Amorfix Life Sciences appoints Aziz Mekouar as a member of Board of Directors

    TSX: AMF

    TORONTO, Jan. 4 /CNW/ - Amorfix Life Sciences is pleased to announce the
appointment of Aziz Mekouar to the company's Board of Directors. "We are
delighted to welcome Mr. Mekouar to our Board," said Graham Strachan, Chair of
the Board of Amorfix. "His substantial business experience and leadership in
global affairs and with the United Nations will be an important asset as
Amorfix continues to pursue its strategic objective of becoming a world leader
in the treatment and diagnosis of misfolded-protein and prion diseases."
    Mr. Mekouar is currently the Ambassador of Morocco to the United States
and participated in the negotiation of the Morocco/United States free trade
agreement and the Millennium Challenge Account wherein the United States
granted US$697 million for Moroccan development projects. He has previously
served as the Ambassador of Morocco to several European countries and other
countries throughout the world. He has also served as Chairman of the Council
and member of the United Nations Food and Agriculture Organization, which
exercises functions dealing with world food and agriculture and related
matters including their impact on human health.
    Mr. Mekouar obtained his business degree from l'Ecole des Hautes
Commerciales of Paris and frequently lectures on the economy and politics in
universities and international conferences.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or

    %SEDAR: 00022789E

For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890